NEW YORK: Braeburn Pharmaceuticals has hired MSLGroup to support the planning and launch of Probuphine, a subdermal implant for the maintenance treatment of opioid dependence in adult patients.
Earlier this month, the US Food and Drug Administration indicated that it would give the product's regulatory application an expedited review.
Jim Weinrebe, EVP at SchwartzMSL Boston, is leading work on the account. Beyond confirming the win, he could say little about the work the firm is doing on the account while the product ...